Menu
Menu
Krystal Integrated Services secures Rs 84.41 crore sanitation contract from PGIMER, Chandigarh. Learn how this facilities management leader is transforming healthcare hygiene standards.
Sun Pharma acquires US-based Checkpoint Therapeutics for Rs 3,084 crore ($355 million), bolstering its oncology portfolio with FDA-approved UNLOXCYT for advanced skin cancer. The deal enhances global access to innovative cancer treatments and aligns with Sun Pharma’s strategy to expand in high-growth specialty therapies. Expected to close by June 2025.
AstraZeneca Pharma India has received regulatory approval to import Eculizumab, a vital treatment for rare blood disorders such as PNH and aHUS. This approval marks a significant step in expanding access to life-saving therapies for patients in India.
Fischer Medical Ventures’ subsidiary, Time Medical International Ventures, has received the CDSCO license to manufacture MRI systems in India. This groundbreaking achievement supports the "Make in India" initiative, boosts local production of high-quality medical devices, and enhances access to advanced diagnostic technology in India and beyond.
Zydus Lifesciences’ subsidiary, Sentynl Therapeutics, achieves a major milestone as the USFDA grants priority review to its New Drug Application (NDA) for CUTX-101, a potential first-of-its-kind therapy for Menkes disease. Backed by promising clinical results showing a nearly 80% reduction in mortality risk, CUTX-101 offers hope for patients battling this rare and fatal pediatric condition. Explore how this development could transform lives and strengthen Zydus’s position in the rare disease segment.
Lupin has acquired the Huminsulin range of insulin products from Eli Lilly in India, significantly expanding its diabetes portfolio. This strategic acquisition will help provide millions of patients with access to affordable, high-quality insulin options for better diabetes management.
Reliance Industries has acquired Karkinos Healthcare for Rs 375 crore, strengthening its healthcare portfolio. This acquisition positions Reliance to expand its presence in the growing field of cancer care, leveraging Karkinos' innovative solutions for early detection and diagnosis.
Shilpa Medicare has achieved a significant milestone with its Unit IV and Unit VII receiving GMP approval from the Eurasian Economic Union. This certification opens up new business opportunities in key markets like Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia, reinforcing the company’s commitment to delivering high-quality pharmaceutical products globally.
Zydus Lifesciences has secured USFDA approval for its Lidocaine and Prilocaine Cream, a topical anesthetic used for pain relief during minor procedures. With significant market potential and production set at their Ahmedabad facility, this approval strengthens Zydus' position in the competitive U.S. generics market.
Glenmark Pharmaceuticals has launched its Lacosamide Oral Solution, a bioequivalent to Vimpat® Oral Solution, offering a more affordable treatment option for partial-onset seizures. This new product enhances access to epilepsy care, with the same therapeutic efficacy as the branded version, making it a valuable option for patients and healthcare providers.